Representativeness of the PIONEER ‐HF and PARAGLIDE‐HF in patients hospitalized with acute heart failure

ConclusionsUsing trial criteria, only 31.3% of AHF patients were eligible for sacubitril –valsartan. Yet, non-eligible patients demonstrated similar outcomes to eligible patients, indicating a need for further evaluation of sacubitril–valsartan benefits in non-eligible AHF patients.

Source: ESC Heart Failure - April 19, 2024 Category: Cardiology Authors: Dong ‐Yi Chen, Chun‐Chi Chen, Cheng‐Hung Lee, Chi‐Nan Tseng, Shao‐Wei Chen, Shang‐Hung Chang, Tien‐Hsing Chen, Pao‐Hsien Chu, I‐Chang Hsieh, Ming‐Shien Wen, Ming‐Lung Tsai, Ming‐Jer Hsieh Tags: Original Article Source Type: research